Sun Pharma enters licensing pact to Italian speciality drug maker Cassiopea Spa
Cassiopea will receive an upfront payment of $45 million, potential commercial milestones totalling up to $190 million and customary double digit royalties. The agreements will close upon the expiration of the HSR waiting period which is 15-30 days.
image for illustrative purpose
Cassiopea will receive an upfront payment of $45 million, potential commercial milestones totalling up to $190 million and customary double digit royalties. The agreements will close upon the expiration of the HSR waiting period which is 15-30 days.
Sun Pharma , on July 26, said it had entered into a licensing and supply pact with Italian speciality drug maker Cassiopea SpA for topical cream Winlevi in US and Canada.
Under the terms of the agreement, Sun Pharma will have the exclusive right to commercialize Winlevi in the US and Canada, and Cassiopea will be the exclusive supplier of the product.
Cassiopea will receive an upfront payment of $45 million, potential commercial milestones totalling up to $190 million and customary double-digit royalties. The agreements will close upon the expiration of the HSR waiting period which is 15-30 days.
